Characterization of Morreton virus as an oncolytic virotherapy platform for liver cancers

Bolni Marius Nagalo, Yumei Zhou, Emilien J. Loeuillard, Chelsae Dumbauld, Oumar Barro, Natalie M. Elliott, Alexander T. Baker, Mansi Arora, James M. Bogenberger, Nathalie Meurice, Joachim Petit, Pedro Luiz Serrano Uson, Faaiq Aslam, Elizabeth Raupach, Musa Gabere, Alexei Basnakian, Camila C. Simoes, Martin J. Cannon, Steven R. Post, Kenneth Buetow, Jean Christopher Chamcheu, Michael T. Barrett, Dan G. Duda, Bertram Jacobs, Richard Vile, Michael A. Barry, Lewis R. Roberts, Sumera Ilyas, Mitesh J. Borad – 1 September 2022

Loss of hepatic SMLR1 causes hepatosteatosis and protects against atherosclerosis due to decreased hepatic VLDL secretion

Willemien Zwol, Antoine Rimbert, Justina C. Wolters, Marieke Smit, Vincent W. Bloks, Niels J. Kloosterhuis, Nicolette C. A. Huijkman, Mirjam H. Koster, Umesh Tharehalli, Simon M. Neck, Colin Bournez, Marceline M. Fuh, Jeroen Kuipers, Sujith Rajan, Alain Bruin, Henry N. Ginsberg, Gerard J. P. Westen, M. Mahmood Hussain, Ludger Scheja, Joerg Heeren, Philip Zimmerman, Bart Sluis, Jan Albert Kuivenhoven – 1 September 2022

Mycophenolate mofetil discontinuation increases severe acute respiratory syndrome coronavirus 2 vaccine response in nonresponder liver transplantation recipients: A proof of concept

Lucy Meunier, Emilie Malezieux, José Ursic Bedoya, Stéphanie Faure, Maxime Echenne, Antoine Debourdeau, Magdalena Meszaros, Georges Philippe Pageaux – 31 August 2022

Antifibrotic effect and long‐term outcome of SGLT2 inhibitors in patients with NAFLD complicated by diabetes mellitus

Taeang Arai, Masanori Atsukawa, Akihito Tsubota, Shigeru Mikami, Uojima Haruki, Keiichiro Yoshikata, Hiroki Ono, Tadamichi Kawano, Yuji Yoshida, Tomohide Tanabe, Tomomi Okubo, Korenobu Hayama, Ai Nakagawa‐Iwashita, Norio Itokawa, Chisa Kondo, Keiko Kaneko, Mototsugu Nagao, Kyoko Inagaki, Izumi Fukuda, Hitoshi Sugihara, Katsuhiko Iwakiri – 29 August 2022 – The aim of this retrospective multicenter study was to clarify the antifibrotic effect and long‐term outcome of sodium glucose cotransporter 2 inhibitors (SGLT2‐Is) in patients with nonalcoholic fatty liver disease (NAFLD) complicated by t

Subscribe to